UW-Madison will provide a paper copy upon request; please contact the University of Wisconsin Police Department. Collects data and monitors test results. $39,400 a year
From University of Wisconsin–Madison - Fri, 09 Jun 2023 00:57:55 GMT - View all Madison, WI jobs

Negotiable: AstraZeneca : Translational Data Science Munich, Germany

Notice NOT-AT-24-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-24-003 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) intends to support the development of innovative methods for quantitative evaluation of myofascial tissues for pain management involving research participants using a two-phase grant funding mechanism. This effort is part of the NIH HEALSM (Helping to End Addiction Long-term) Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is bolstering research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management. This notice of funding opportunity (NOFO) seeks research applications to develop quantitative measures of myofascial tissues and assess their abilities to detect changes to myofascial tissues across a variety of pain management interventions. Candidate objective measures may be based on minimally invasive imaging technologies, electrophysiological recordings, integration of multiparametric imaging and electrophysiology approaches, or their integration with other markers (e.g., immune factors, genomic markers, physiological factors) through multiscale modeling or machine learning analysis. The first phase, funded by the R61, will provide funding for up to 3 years to develop quantitative measures that can differentiate abnormal myofascial tissue from healthy tissues using cross-sectional correlations with clinical signs/symptoms. In addition, the R61 phase should include planning activities for the R33 phase. The second phase, funded under the R33, will provide support to assess the abilities of the quantitative measures developed in the R61 phase to measure tissue changes in response to therapies or manipulations that may relieve pain using rigorous, longitudinal clinical study design. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful co

Funding Opportunity RFA-AG-24-026 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites R34 applications to support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- and late-life). Applications suited to this R34 will focus on planning activities for social network interventions for which a target interpersonal process of behavior change or social network characteristic has already been identified. Planning activities are those activities that are expected to yield necessary and sufficient information to inform final decisions about a social network health behavior change intervention prior to instigation of a hypothesis-driven trial to test a social network intervention. Activities may include (but are not limited to) team-building, protocol development, piloting of systems for data collection and/or management, feasibility and acceptability testing, staff training, and establishing documentation procedures. Basic experimental and observational behavioral and/or social science applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks are outside the scope of this RFA. Research to identify targets for future social network health behavior change interventions and/or to develop, refine, or optimize measures (assays) of putative targets are also outside the scope of this RFA. Both of these types of research are most appropriate for the companion R01 RFA (RFA-AG-24-025). Projects that propose to test the efficacy or effectiveness of a social network health behavior change intervention are also outside the scope of this RFA, which focuses only on pre-trial planning and development activities.

Funding Opportunity RFA-AG-24-025 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics. Projects will identify targets for future social network health behavior change interventions across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- to- late life). Basic research to develop, refine, or optimize measures (assays) of putative targets (e.g., intra/interpersonal mechanisms of behavior change and/or social network characteristics) are also supported by this NOFO. Clinical trials that do not meet the federal definition of basic research (CFR 272.3) are not responsive to this RFA. Projects that propose to support the planning activities necessary to develop social network interventions for which a target has already been identified are most appropriate for the R34 RFA companion (RFA-AG-24-026).

Notice NOT-NS-23-071 from the NIH Guide for Grants and Contracts

Notice NOT-TR-23-021 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-070 from the NIH Guide for Grants and Contracts

Notice NOT-TR-23-020 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-089 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: EMBL is Europe’s life sciences laboratory – an intergovernmental organisation with more than 110 independent research groups and service teams coverin Germany (DE)

Notice NOT-RM-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-015 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-016 from the NIH Guide for Grants and Contracts

Notice NOT-RM-23-017 from the NIH Guide for Grants and Contracts

Negotiable: AstraZeneca : Job Opportunity: Executive Director, In Silico Biologics Discovery Location: Cambridge - UK (Granta Park / Cambridge Biomedical Campus) / Gaithersbur Cambridgeshire, England

DNA sequencing and bioinformatic analysis (Illumina, PacBio, Nanopore). Develop and perform next generation sequencing, including sample preparation and… $82,000 - $110,000 a year
From Shape Therapeutics - Tue, 06 Jun 2023 20:31:50 GMT - View all Seattle, WA jobs

£34,619 - £43,592 per annum: Barts Cancer Institute , Queen Mary University London: Department: Barts Cancer Institute Salary: £34,619 - £43,592 per annum (Grade 4) Reference: QMUL31609 Location: Charterhouse Square Date posted: 3 Apr London, Greater London, England

Notice NOT-DK-23-029 from the NIH Guide for Grants and Contracts